To validate the association among Fstl1, DIP2A, and MGMT in clinical samples, we measured the levels of these three proteins in 19 MGMT promoter–hypomethylation (MGMT methylation ≤ 13%) GBM clinical samples (Fig. 8c). The gene discussed is MGMT; the disease is glioblastoma.